chufangao/CTO huggingface dataset:
Clinical trial NCT02928224: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Official title: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Acronym: BEACON CRC
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 702.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-10-13
Primary completion date: 2019-02-11
Completion date: 2022-11-10
Baseline population: The baseline analysis population consists of the Full Analysis Set (FAS). For participants in the CSLI, the FAS includes all participants who received at least 1 dose of study drug and had at least 1 post treatment assessment, which may include death. For the randomized Phase 3 portion of the study, the FAS consists of all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04435366: A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
Official title: A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 448.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-22
Primary completion date: 2022-07-25
Completion date: 2023-08-22
Clinical trial NCT04076761: Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
Official title: A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial)
Acronym: MOCHA
Sponsor: Sunnybrook Health Sciences Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Funding
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-11
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Clinical trial NCT05018975: Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
Official title: Repurposing Tazemetostat for the Treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 Patient
Acronym: IST
Sponsor: Loma Linda University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: FDA recommendation cited safety issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-09-21
Completion date: 2023-09-21
Clinical trial NCT03787147: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI)
Official title: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI)
Acronym: VR adult
Sponsor: Albert Einstein College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Never started the study cause of the lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-30
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Plan to share individual participant data: NO
Clinical trial NCT03086369: A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Official title: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 184.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-06-22
Primary completion date: 2021-01-05
Completion date: 2021-06-17
Baseline population: All participants in phase 1b/2.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT05450549: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
Official title: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
Sponsor: Denali Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-14
Primary completion date: 2023-06-08
Completion date: 2023-06-08
Plan to share individual participant data: NO
Clinical trial NCT04954196: Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index
Official title: Benefit of Amlodipine in HRT Cycle (Hormone Replacement Therapy) for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index: Randomized Controlled Double-blind Trial.
Acronym: AMLODIP
Sponsor: University Hospital, Montpellier (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-08
Primary completion date: 2023-10-08
Completion date: 2024-09-08
Clinical trial NCT03177252: Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients
Official title: Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients
Acronym: Scalp block
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Investigator decided not to go forward with the trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-01
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT04535986: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Official title: A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Sponsor: Verona Pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 763.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-29
Primary completion date: 2022-09-12
Completion date: 2022-12-02
Baseline population: All patients randomized set included all patients in the enrolled set who were randomized to study medication.
Clinical trial NCT04504708: Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Official title: A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study terminated early due to business decision.
Enrollment: 6.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-02-17
Primary completion date: 2022-07-08
Completion date: 2022-07-08
Clinical trial NCT00390793: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
Official title: Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 107.0 (ACTUAL)
Number of arms: 1.0
Start date: 2006-09-28
Primary completion date: 2024-02-02
Completion date: 2024-02-02
Clinical trial NCT00005044: Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Official title: A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1579.0 (ACTUAL)
Number of arms: 2.0
Start date: 2000-02-29
Primary completion date: 2012-09-30
Completion date: 2022-05-20
Baseline population: Eligible patients with follow-up data
Limitations and caveats: The data monitoring committee decided in June 2012 after the first interim analysis that the trial should be reported early due to the low number of events.
Clinical trial NCT01964430: Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study)
Official title: A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Acronym: apact
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 866.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-28
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Baseline population: The Intent-to-treat (ITT) population consisted of all randomized participants regardless of whether the participant received any investigational product (IP) or had any efficacy assessments collected.
Clinical trial NCT02150967: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Official title: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Sponsor: QED Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints). Termination was not due to concerns about safety and had no impact on the primary efficacy analysis (ie, results reported for Cohort 1).
Enrollment: 143.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-07-23
Primary completion date: 2021-03-01
Completion date: 2022-02-07
Baseline population: Full Analysis Set (FAS), defined as all subjects who had received at least 1 dose of infigratinib.
Plan to share individual participant data: NO
Clinical trial NCT03513458: Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation
Official title: Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation
Acronym: LateAna
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: \[The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
IPD sharing description: The investigators will not be sharing individual participant data (IPD) with other researchers.
Clinical trial NCT03889639: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
Official title: A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 8.0
Start date: 2019-03-29
Primary completion date: 2020-01-02
Completion date: 2020-01-02
Baseline population: Baseline analysis was performed on randomized population that included any participant who had been allocated to a randomly assigned treatment, regardless of whether the treatment kit was used.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04329949: Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Official title: A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)
Acronym: RELIANT
Sponsor: Corcept Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-30
Primary completion date: 2021-08-23
Completion date: 2022-03-25
Baseline population: All enrolled patients
Limitations and caveats: The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
Plan to share individual participant data: NO
Clinical trial NCT06124924: SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Official title: SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Poor recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-04-01
Primary completion date: 2024-08-16
Completion date: 2024-08-16
Clinical trial NCT05849246: The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Official title: Open-label, Phase 2 Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: strategy terminates development, the decision is not due to any safety-related issues
Enrollment: 4.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-07-31
Primary completion date: 2023-11-30
Completion date: 2023-12-22
Clinical trial NCT03338010: A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Official title: A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 536.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-22
Primary completion date: 2020-03-18
Completion date: 2020-03-18
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03791060: Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Official title: An Open-label Proof of Concept Study Regarding the Use of Secukinumab (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-03
Primary completion date: 2021-01-17
Completion date: 2021-04-10
Baseline population: Patient characteristics and demographic data will be presented using descriptive statistics.
Plan to share individual participant data: NO
Clinical trial NCT05226390: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
Official title: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study
Sponsor: Hannover Medical School (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: cohort could not be recruited
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-24
Primary completion date: 2023-11-21
Completion date: 2023-11-21
Plan to share individual participant data: NO
Clinical trial NCT04125810: A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychological Stress
Official title: A Randomized, Triple-blind, Placebo-controlled, Parallel-groups Clinical Trial to Assess the Safety and Efficacy of Lactobacillus Paracasei (Lpc-37) to Modulate Psychological Stress
Sponsor: Danisco (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 190.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-02
Primary completion date: 2020-02-07
Completion date: 2020-02-07
Plan to share individual participant data: NO
Clinical trial NCT04722809: Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology
Official title: Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology
Acronym: Botox
Sponsor: Centre Hospitalier Universitaire Dijon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulties in recruiting patients, compounded by problems extracting data from the device used in the study.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-25
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Clinical trial NCT04069936: Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
Official title: A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Subjects With Locally Advanced and Unresectable or Metastatic NSCLC Previously Treated With Anti-PD-1
Sponsor: WindMIL Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Resourcing
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-15
Primary completion date: 2021-10-28
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT03928015: Evaluation of Dronabinol For Acute Pain Following Traumatic Injury
Official title: A Single Centre Randomized Controlled Trial To Evaluate Dronabinol For Acute Pain Management In Adults With Traumatic Injury
Sponsor: CommonSpirit Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: This trial did not enroll subjects. After initial approval we procured an appropriate placebo. Before IRB the amendment was approved, the COVID-19 pandemic placed a hold on all non-essential research activity at the enrolling hospital.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-01
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Plan to share individual participant data: NO
Clinical trial NCT03883893: IV Acetaminophen and Post-Tonsillectomy Pain
Official title: Randomized Prospective Study Investigating the Analgesic Efficacy of Intravenous Acetaminophen in Reducing Post-Tonsillectomy Pain in Pediatric Patients
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Mentor for PI left institution. Study was not renewed.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2022-10-31
Completion date: 2023-04-30
Clinical trial NCT03708536: Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
Official title: Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial
Sponsor: Fujian Cancer Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: There are no fund to support
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-30
Primary completion date: 2021-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT04426357: A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
Official title: A Single-dose, Open-label, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
Sponsor: Janssen Pharmaceutica N.V., Belgium (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: company decision
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-03
Primary completion date: 2020-11-12
Completion date: 2020-11-12
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu